On 3/10/25, Neogenomics Inc (NASDAQ: NEO) stock suffered a major decline of -10.0%, closing at $9.09. Moreover, this decline was accompanied by above average trading volume at 139% of normal. Relative to the market the stock has been weak over the last nine months and has declined -9.1% during the last week.
Current PriceTarget Research Rating
Neogenomics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Neogenomics has a slightly negative Appreciation Score of 40 and a poor Power Rating of 27, with the Negative Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment